Navigation Links
Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors
Date:11/18/2010

g, including statements related to future preclinical and clinical development plans for its product candidates. These forward-looking statements represent Oncothyreon's intentions, plans, expectations and beliefs and are based on its management's experience and assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties, including risks and uncertainties related to Oncothyreon's business and the general economic environment. Many of these risks and uncertainties are beyond Oncothyreon's control. These risks, uncertainties and other factors could cause Oncothyreon's actual results to differ materially from those projected in forward-looking statements. Risks, uncertainties, and assumptions include those predicting the timing, duration and results of clinical trials, the timing and results of regulatory reviews, the safety and efficacy of Oncothyreon's product candidates, and the indications for which Oncothyreon's product candidates might be developed. There can be no guarantee that the results of preclinical studies or clinical trials will be predictive of either safety or efficacy in future clinical trials. These and other risks and uncertainties are described in the reports and other documents filed by Oncothyreon Inc. with the SEC and/or Canadian regulatory authorities.

Although Oncothyreon believes that any forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of the risks and uncertainties associated with Oncothyreon, you are encouraged to review the official corporate documents filed with the securities regulators in the United States on U.S. EDGAR and in Canada on SEDAR. Oncothyreon is under no obligation to
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Oncothyreon Reports Third Quarter 2010 Financial Results
2. Oncothyreon to Present at JMP Securities Healthcare Conference
3. ONCOTHYREON ANNOUNCES PRICING OF $14.9 MILLION PRIVATE PLACEMENT
4. ONCOTHYREON APPOINTS JULIE M. EASTLAND AS CHIEF FINANCIAL OFFICER
5. Oncothyreon reports second quarter 2010 financial results
6. Oncothyreon announces second quarter 2010 financial results conference call
7. Oncothyreon announces presentations at upcoming investor conferences in June
8. Oncothyreon to present at the Rodman & Renshaw Annual Global Investment Conference
9. Oncothyreon reports full year and fourth quarter 2009 financial results
10. Oncothyreon reports first quarter 2010 financial results
11. Oncothyreon announces temporary suspension of Stimuvax clinical trials by Merck Serono
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... San Francisco, CA (PRWEB) , ... June 30, ... ... in FMT Patients , Study will provide new insights on mechanics of fecal ... announced a new partnership to study the microbiome of patients undergoing fecal microbiota ...
(Date:6/30/2015)... ... 30, 2015 , ... The maximum number of shares proposed to be purchased ... shares of unvested restricted stock). On June 29, 2015, the last trading day prior ... reported on the OTCBB was $2.29 per share. , The tender offer will expire ...
(Date:6/30/2015)... N.Y. , June 30, 2015  Custom Computer ... announced today that they are silver sponsors of the ... official PCDC sponsor, Custom is lending their support of ... low-income communities. Since its founding in 1993, ... the primary care area.  PCDC has financed over 100 ...
(Date:6/30/2015)... Edwardsville, IL (PRWEB) , ... June 30, 2015 ... ... resigned effective August 14. She has accepted the position of vice president of ... on August 17. , “I greatly appreciated the opportunity to lead SIUE ...
Breaking Biology Technology:uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3Custom Computer Specialists Announces Sponsorship Of The Primary Care Development Corporation's Corporate Circle 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 3
... 2011 Cross reference:   Picture ... be downloaded free of charge at:   http://www.presseportal.de/pm/18701/eppendorf-ag?keygroup=bild ... Science from 2008, Dr. Andrew Holt and ... how chemicals used as manufacturing additives can substantially inhibit ...
... HANOVER, N.J., Dec. 2, 2011 Novartis Pharmaceuticals Corporation ... presentations on data from its robust oncology portfolio at ... for patients with cancers and hematological diseases. ... held from December 6-10, will feature data presentations from ...
... Ltd. - (OTCBB: HADSY), a publicly traded portfolio of ... owned by the Hadassah University Hospital, Israel,s foremost medical ... companies have received grant approvals from the Israeli Office ... Industry, Trade and Labor. These approvals ...
Cached Biology Technology:Eppendorf Video Features Dr Andrew Holt's Work on Bioactive Leachates From Plastic Consumables 2Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 2Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 3Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 4Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 5Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 6Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 7Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 8Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 9Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 10Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 11Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 12Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 13Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 14Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 15Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 16Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 17Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 18Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 19Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 20Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 21Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies 2
(Date:6/25/2015)...  Imagine a tool specifically designed to help you ... That,s exactly what USANA,s True Health Assessment ... health program provides a personalized approached to measuring your ... lifestyle and nutrition. At the Canadian ... USANA,s THA was honored with the Industry Innovation Award. ...
(Date:6/24/2015)... June 24, 2015 This report provides market ... next six years. It contains an analysis of the ... with their impact from the short, medium, and long ... the industry, market, and technology trends that currently, prevail ... of concerned authorities to efficiently manage the increasing marine ...
(Date:6/24/2015)... MARTIGNY, Switzerland , June 24, 2015 /PRNewswire/ ... strategic partnership with emerging biometric password solution one ... http://photos.prnewswire.com/prnh/20150623/225014LOGO one face in, ... offers a ground-breaking and affordable multifactor-authentication biometric answer ... speaker recognition technology, provided in partnership with KeyLemon, ...
Breaking Biology News(10 mins):@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... researchers and collaborators have found, in a previously identified ... five cases of isolated cleft lip. It is the ... cleft lip alone, rather than both cleft lip and ... unknown genetic mechanism and could eventually help with diagnosis, ...
... Journal of Cell Biology how the altered behavior ... On 2D surfaces, cells may migrate randomly, or be ... extracellular matrix, are known to influence the mode of ... has suggested that an integrin called a5b1 drives random ...
... New material could speed development of hydrogen powered vehicles ... design of a new material that almost meets the U.S. ... could help eliminate a key roadblock to practical hydrogen-powered vehicles. ... explosive gas, is scheduled for the Oct. 8 issue of ...
Cached Biology News:Study finds genetic variant plays role in cleft lip 2Study finds genetic variant plays role in cleft lip 3American Chemical Society's Weekly PressPac 2American Chemical Society's Weekly PressPac 3American Chemical Society's Weekly PressPac 4American Chemical Society's Weekly PressPac 5American Chemical Society's Weekly PressPac 6American Chemical Society's Weekly PressPac 7American Chemical Society's Weekly PressPac 8
Mouse polyclonal antibody to GRID2 - glutamate receptor, ionotropic, delta 2...
... is a direct antibiotic-based selection system for ... colony survival, eliminating the need for costly ... provides close to 100% accuracy in recombinant ... for robot colony picking. This cloning kit ...
Mouse polyclonal antibody raised against a partial recombinant KCTD13. NCBI Entrez Gene ID = 253980...
Mouse monoclonal antibody raised against a partial recombinant FAAH. NCBI Entrez Gene ID = FAAH...
Biology Products: